FUERER CORNEL B

FUERER CORNEL B sold 55,242 CTVA shares at $68.06 on 2025-05-13, reducing holdings by 35.2%; his prior CTVA sells have been well-timed at 90 days.

Cornel Fuerer sold 55,242 shares of Corteva at $68.06, cutting his holdings from 156,883 to 101,641 shares (35.2% reduction). The transaction occurs near the 52-week high of $68.29, and notably, his prior open-market sales at CTVA (on 2024-11-26 and 2024-05-14) both yielded negative 90-day returns of -1.2% and -10.8%, respectively, establishing a pattern of well-timed exits over a 12-month period. His cross-ticker track record reinforces this pattern: 2 prior sells with a 100% 90-day well-timed rate and an average 90-day return of -6.0%, indicating a history of selling ahead of declines. The current sale, executed at a price 0.0% from the 52-week high, aligns with his demonstrated pattern of discretionary timing around price peaks. Investors should monitor whether this transaction signals similar insight into near-term weakness, particularly given the company's flat annual revenue growth of -1.8% and elevated P/E of 40.89.

SVP Fuerer sells 37,672 CTVA shares at $63.40; prior 2024 sale well-timed as stock fell -10.8% thereafter

Cornel B. Fuerer, SVP, General Counsel and Secretary, sold 37,672 shares (127.0K held post-transaction) at $63.40 on 2024-11-26 for $2,388,367.13. This represents a -22.9% reduction in his CTVA position. His track record at this ticker shows strong timing: a May 2024 sale preceded a -10.8% 90-day decline, and a November 2023 buy preceded a +23.5% 90-day rise. The current stock price of $62.50 is -2.5% from the 52-week high of $64.13, while the company reports a net income loss of $-524,000,000.00 against $2,326,000,000.00 in quarterly revenue, with a notably elevated P/E of 61.88. The sequence of his prior two trades being well-timed at the 90-day mark may merit investor attention as a potential signal, though the company's profitability headwinds appear concurrent with the decision.